Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125564341 | 12556434 | 1 | I | 20151223 | 20160617 | 20160714 | 20160714 | EXP | US-AMGEN-USASL2016079674 | AMGEN | 65.00 | YR | E | F | Y | 62.13000 | KG | 20160714 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125564341 | 12556434 | 1 | PS | PROLIA | DENOSUMAB | 1 | Subcutaneous | 60 MG/ML, Q6MO | 125320 | SOLUTION FOR INJECTION | |||||||||
| 125564341 | 12556434 | 2 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | 1 MG, QMO | 0 | 1 | MG | /month | ||||||||
| 125564341 | 12556434 | 3 | C | VOLTAREN | DICLOFENAC SODIUM | 1 | UNK UNK, AS NECESSARY | 0 | |||||||||||
| 125564341 | 12556434 | 4 | C | LIDOCAINE. | LIDOCAINE | 1 | Topical | UNK UNK, AS NECESSARY | 0 | ||||||||||
| 125564341 | 12556434 | 5 | C | LORAZEPAM. | LORAZEPAM | 1 | 1 MG, Q6H | 0 | 1 | MG | QID | ||||||||
| 125564341 | 12556434 | 6 | C | ASPIRIN. | ASPIRIN | 1 | 81 MG, QD | 0 | 81 | MG | QD | ||||||||
| 125564341 | 12556434 | 7 | C | COREG | CARVEDILOL | 1 | 25 MG, BID | 0 | 25 | MG | BID | ||||||||
| 125564341 | 12556434 | 8 | C | GABAPENTIN. | GABAPENTIN | 1 | 300 MG, TID | 0 | 300 | MG | TID | ||||||||
| 125564341 | 12556434 | 9 | C | LISINOPRIL. | LISINOPRIL | 1 | 10 MG, BID | 0 | 10 | MG | BID | ||||||||
| 125564341 | 12556434 | 10 | C | MAGNESIUM OXIDE. | MAGNESIUM OXIDE | 1 | 250 MG, BID | 0 | 250 | MG | BID | ||||||||
| 125564341 | 12556434 | 11 | C | OXYBUTYNIN | OXYBUTYNIN | 1 | 5 MG, QD | 0 | 5 | MG | QD | ||||||||
| 125564341 | 12556434 | 12 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 25 MG, QD | 0 | 25 | MG | QD | ||||||||
| 125564341 | 12556434 | 13 | C | TIZANIDINE. | TIZANIDINE | 1 | 4 MG, QD | 0 | 4 | MG | QD | ||||||||
| 125564341 | 12556434 | 14 | C | EFFEXOR | VENLAFAXINE HYDROCHLORIDE | 1 | 75 MG, BID | 0 | 75 | MG | BID | ||||||||
| 125564341 | 12556434 | 15 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 | ||||||||||||
| 125564341 | 12556434 | 16 | C | CALCIUM | CALCIUM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125564341 | 12556434 | 1 | Osteoporosis postmenopausal |
| 125564341 | 12556434 | 5 | Anxiety |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125564341 | 12556434 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125564341 | 12556434 | Adverse reaction | |
| 125564341 | 12556434 | Bone pain | |
| 125564341 | 12556434 | Cystitis | |
| 125564341 | 12556434 | Drug intolerance | |
| 125564341 | 12556434 | Dysuria | |
| 125564341 | 12556434 | Hypersensitivity | |
| 125564341 | 12556434 | Injection site pruritus | |
| 125564341 | 12556434 | Pelvic fracture | |
| 125564341 | 12556434 | Pruritus | |
| 125564341 | 12556434 | Skin fissures | |
| 125564341 | 12556434 | Urticaria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125564341 | 12556434 | 1 | 20151223 | 0 |